F5, Inc. Securities Fraud Investigation

April 13, 2026

Shamis & Gentile, P.A. is investigating claims on behalf of investors of F5, Inc. ("F5" or the "Company") (FFIV). Impacted investors are advised to contact the firm now.

The law firm is investigating whether F5 misrepresented or failed to disclose material information regarding the Company’s cybersecurity posture, internal controls, and risk disclosures between October 2024 through October 2025. During this time, F5 allegedly made positive statements in earnings releases, SEC filings, and investor presentations about the reliability of its core BIG-IP products.

On October 15, 2025, F5 filed a Form 8-K with the SEC confirming that attackers had accessed its BIG-IP development environment and stolen proprietary code and vulnerability data. This was the first public acknowledgment of the breach. The following day, multiple outlets attributed the attack to Chinese state-linked hackers, and the U.S. Cybersecurity and Infrastructure Security Agency (CISA) issued an emergency directive warning federal agencies about the incident’s severity.

On this news, F5’s stock price fell approximately $36 per share, or about 12%, closing at $295.35 on October 16, 2025, causing significant harm to investors.

If you purchased F5 (NASDAQ: FFIV) securities between October 2024 and October 2025, you may be eligible to seek compensation for your losses. Contact Shamis & Gentile, P.A. today to discuss your options.

Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis & Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise and resources enable the firm to resolve disputes in a wide range of matters, including class actions, mass torts and mass arbitrations.

Attorney advertising. Prior results do not guarantee similar outcomes.